In another example, a US-managed care provider is using UiPath to tackle a backlog of more than 140,000 provider appeals. Agents classify forms, robots handle the processing, and Maestro orchestrates ...

UiPath Inc (NYSE: PATH) stocks surged after reporting strong Q3 results, with Canaccord Genuity analyst raising price target to $19 and Needham maintaining Hold rating.

UiPath reported quarterly adjusted earnings of 16 cents per share, which beat the Street estimate of 15 cents. Quarterly ...

Q3 2026 Earnings Call Transcript December 3, 2025 UiPath Inc. beats earnings expectations. Reported EPS is $0.16, expectations were $0.14. Operator: Greetings, and welcome to the UiPath Third Quarter ...

Automation software company UiPath (NYSE:PATH) announced in Q3 CY2025, with sales up 15.9% year on year to $411.1 million.

From fiscal 2021 to 2025, which ended in January, UiPath's revenue grew at a CAGR of 24% from $608 million to $1.4 billion.

Now, it’s worth noting Stock Advisor’s total average return is 1,004% — a market-crushing outperformance compared to 194 % ...

UiPath is deepening its role inside enterprise workflows, and institutional capital is noticing. This breakdown highlights ...

Power Automate sits at the center of Microsoft’s automation stack and links Outlook, SharePoint, Excel, Dynamics 365, Teams ...

UiPath Inc. PATH shares have been flat year to date and are down 15% over the past three months. This performance suggests ...

Automat develops human-like AI agents to simplify enterprise automation and replace legacy automation tools for enterprise workflows.

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track multiple gene mutations while simultaneously recording gene activity in ...